• Explore /
  • Poster
  • / Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma.

Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma.

Abstract Poster

Authors

null

Armin Ghobadi

Washington University School of Medicine, St. Louis, MO

Armin Ghobadi , L Elizabeth Budde , Ahmed Galal , Kristina Stermer , TaShara Lynn Austin , Jean Fan , John F. DiPersio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT05075603

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7596)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7596

Abstract #

TPS7596

Poster Bd #

239b

Abstract Disclosures

Similar Posters

First Author: Sairah Ahmed

First Author: Boyu Hu

First Author: Frederick L. Locke

First Author: Frederick L. Locke